Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xbrane Biopharma AB

Latest From Xbrane Biopharma AB

Stada Set To Minimize Xbrane Ownership As Swedish Firm Hunts For Cash

“We are extremely well aware of the consequences for investors that cannot protect their ownership share in this transaction,” Xbrane has told its investors, as the Swedish firm looks to tie up much-needed capital injection via a right issue to fuel its pipeline of biosimilar projects.

Financing Strategy

Who’s Hired? Rosemont Drives M&A With New Appointments

UK liquids specialist Rosemont Pharmaceuticals has appointed a new chief corporate development officer to drive M&A. Meanwhile, EuroAPI has named a chief transformation officer, Zentiva’s CEO has joined Medicines for Europe’s executive committee, Hikma has changed company secretary, and Xbrane has made alterations to its nominations committee.

Executive Changes Leadership

Xbrane Drops Keytruda Rival As It Pares Down Pipeline And Personnel

Swedish biosimilars developer Xbrane Biopharma has revealed that it is dropping development of its planned Xtrudane pembrolizumab biosimilar to Keytruda, as part of a move towards a more “focused development portfolio.” At the same time, the firm has announced job cuts as part of a new cost-savings scheme designed to help the firm “achieve a positive cash flow as soon as possible.”

Strategy Biosimilars

Xbrane: We Are Not Convinced On European IQVIA Ranibizumab Data

Swedish biosimilars player Xbrane spoke candidly about its recent launch of the company’s first product, the Stada-partnered Ximluci biosimilar to Lucentis in Europe, as it updated on the company’s ongoing hunt for a new US commercialization partner.

Sales & Earnings Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Primm Pharma Srl